Objective To determine the efficacy and safety of treatment with rituximab plus methotrexate
(MTX) in patients with active rheumatoid arthritis (RA) who had an inadequate response to …

Objective To assess the safety, tolerability, biologic activity, and efficacy of belimumab in
combination with standard of care therapy (SOC) in patients with active systemic lupus …

Lupus nephritis is a potentially fatal autoimmune disease for which the current treatment is
ineffective and often toxic. To develop mechanistic hypotheses of disease, we analyzed …

Objective To describe a new systemic lupus erythematosus (SLE) responder index (SRI) based
on a belimumab phase II SLE trial and demonstrate its potential utility in SLE clinical trials…

Background Patients with systemic lupus erythematosus have substantial unmet medical
need. Baricitinib is an oral selective Janus kinase (JAK)1 and JAK2 inhibitor that we …

Objective Randomised trials of type I anti-CD20 antibodies rituximab and ocrelizumab failed
to show benefit in proliferative lupus nephritis (LN). We compared obinutuzumab, a …

Background Type I interferons are involved in systemic lupus erythematosus (SLE)
pathogenesis. In a phase 2 trial, anifrolumab, a human monoclonal antibody to type I interferon …

Objective To investigate the efficacy and safety of ocrelizumab in patients with class III/IV
lupus nephritis (LN). Methods Patients were randomized 1:1:1 to receive placebo, 400 mg …

Background Blood dendritic cell antigen 2 (BDCA2) is a receptor that is exclusively
expressed on plasmacytoid dendritic cells, which are implicated in the pathogenesis of lupus …

Background Antibody-binding of blood dendritic cell antigen 2 (BDCA2), which is expressed
exclusively on plasmacytoid dendritic cells, suppresses the production of type I interferon …